Skip to main content

Table 2 Background characteristics of frailty and cognitive function

From: Prevalence of frailty, cognitive impairment, and sarcopenia in outpatients with cardiometabolic disease in a frailty clinic

Frailty status

 mCHS status (n = 303)

 Robust (%)

26.1

 Prefrailty (%)

49.8

 Frailty (%)

24.1

 Frailty (%) by CFS (n = 315)

31.7

 Frailty (%) by KCL (n = 311)

33.8

 Frailty (%) by TMIG-IC (n = 320)

26.6

Cognitive function

 MMSE (n = 320)

28 (26–29)

 HDS-R (n = 320)

27 (24–29)

 MoCA-J (n = 320)

22 (19–25)

 DASC-21 (n = 264)

24 (23–27)

 Cognitive impairment

 MMSE ≤27 (%)(n = 320)

40.9

 MoCA -J ≤ 25 (%)(n = 320)

84.1

 Suspected dementia

 MMSE ≤23 (%)(n = 320)

12.8

 HDS-R ≤ 20 (%)(n = 320)

11.6

 DASC-21 ≥ 31 (%)(n = 264)

14.8

  1. Abbreviations: SMI Skeletal Muscle Mass Index, TUG Timed up and go test For continuous variables, values indicate median (25–75th percentile)